NameAkash Jaiswal Asfaque Ahmed Amiya kumar Mishra Team -2

India·s 1st billion dollar biotech company.


} ESTABLISHED IN 1978 } HEADQUARTERS- BANGLORE, INDIA HEADQUARTERS} FOUNDER- KIRAN MAZUNDAR- SHAW FOUNDERMAZUNDAR} PRODUCTS- Related to Cardiology, oncology, PRODUCTSnephrology, Diabetology. Diabetology. } Revenue- Rs. 2,405 Crore (us$545.94 million) Revenue- Rs. } EMPLOYEES- 4,750 (2010) EMPLOYEES-

To be an integrated biotechnology enterprise of global distinction. distinction.

To promote social and economic inclusion by ensuring that marginalized communities have equal access to healthcare services and educational opportunities.

Biocon Values

} Focus on people. } Diversity. } Trust, Integrity and Commitment. } Quality First } Innovation Innovation.


} 2010- BIO EXCELLANCE AWARD for out standing achievement in Health care Sector. } 2009- Among top 20 companies in Forbes¶ best under A Billion list. } 2008- 7th largest Biotech Employer in world (June) } 2007- Biocon buys 70% stake of the German Pharma Axicorp in a ¼ 30 million deal. } 2006- Best IT user firm in Pharmaceutical Sector.

Product and service
} Product :
} Biopharmaceuticals } Enzymes } Food Additive

} Service :
} Custom Research } Clinical Research } CSR

‡Biocon R&D expertise ‡Highly skilled man power ‡Strategic alliances and acquisitions (Axicorp) ‡Manufacturing Sites limited to India ‡Statin dependent





‡Global pharmaceutical market US$ 400 Billion ‡Regulated generic market estimated at US $ 38 billion

‡ Regulatory risk ‡ Competitive threat (Amgen and Biogen)

According to Resources‡ Financial ‡ Operating cash Income:832.35Cr, Credit rating: A+ ‡ ‡ Physical Resources ‡ Market value of fixed assets:715 Cr

Tangible Resources

In Tangible Recourses

‡ Patents: 205 Granted Patents

Organizational Capabilities

‡ Core Competence in Fermentation (Plafractor ± a solid state fermentation reactor) ‡ Highly skilled manpo er

Business strategy«..

Crystal Gazing
Kiran M. shaw steered the company through several reinventions


Biopharma Statins

Biocon, Syngene and Clinigene which is the main business.

Enzyme makers

Strategic statement-

} ³ we keep reinventing our self, in the first 20 years we focused on enzymes, in last 10 year we focused biopharma and services we now want to get into the market with our own products it was the first about branded enzymes, now it is about branded Biopharma´

Sign up to vote on this title
UsefulNot useful